Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
First-Line PFS - ALECENSA® (alectinib)
Frontiers | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment | Oncology
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients | Oncology
Alectinib & crizotinib improved survival outcomes of NSCLC | OTT
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials - Journal of Thoracic Oncology
Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib - Clinical Lung Cancer
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib | Journal of Comparative Effectiveness Research
New standards of care for ALK-positive disease - memoinOncology
Roche - European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
YIR On Demand Lung Benjamin Levy, MD Assistant Professor - ppt download
First-Line PFS - ALECENSA® (alectinib)
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis - Fan - 2018 - Cancer Medicine - Wiley Online Library
Progression-free survival of patients with ALK-positive NSCLC | Download Scientific Diagram
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
